Celgene

UK gets early access to Roche’s breast cancer immunotherapy
UK gets early access to Roche’s breast cancer immunotherapy
Pharmaforum
Roche
Tecentriq
Celgene
Abraxane
UK
triple-negative breast cancer
Flag link:
Is Celgene and Bristol-Myers a Match Made in Heaven or Doomed to Fail?
Is Celgene and Bristol-Myers a Match Made in Heaven or Doomed to Fail?
Motley Fool
M&A
Bristol-Myers Squibb
Celgene
Flag link:
U.S. court rejects Alvogen's patent challenge for Celgene's cancer drug
U.S. court rejects Alvogen's patent challenge for Celgene's cancer drug
Yahoo/Reuters
Celgene
Revlimid
patents
Multiple Myeloma
Alvogen
Flag link:
Celgene’s Abraxane Fails to Hit the Mark in a Phase III Pancreatic Cancer Study
Celgene’s Abraxane Fails to Hit the Mark in a Phase III Pancreatic Cancer Study
BioSpace
Celgene
Abraxane
clinical trials
pancreatic cancer
Flag link:
How This Looming Patent Battle Could Challenge Bristol-Celgene Deal
How This Looming Patent Battle Could Challenge Bristol-Celgene Deal
Investors Business Daily
Celgene
Novartis
ozanimod
MS
multiple sclerosis
patents
Bristol-Myers Squibb
M&A
Flag link:
Bristol-Myers CEO Caforio wants M&A dissidents to know there's been no 'high level' overtures about buying the company since '17
Bristol-Myers CEO Caforio wants M&A dissidents to know there's been no 'high level' overtures about buying the company since '17
Endpoints
Bristol-Myers Squibb
Celgene
Giovanni Caforio
M&A
Flag link:
Celgene Submits MS Drug for Approval in Europe, FDA Filing on Track
Celgene Submits MS Drug for Approval in Europe, FDA Filing on Track
Xconomy
Celgene
Bristol-Myers Squibb
Europe
FDA
M&A
MS
multiple sclerosis
ozanimod
Flag link:
Does Bristol-Myers have a plan B if activists scuttle its Celgene buy?
Does Bristol-Myers have a plan B if activists scuttle its Celgene buy?
Fierce Pharma
Bristol-Myers Squibb
Celgene
M&A
Flag link:
It’s what Bristol-Myers execs aren’t saying that makes one key analyst wonder about a potential buyout offer, looming Opdivo data and Plan B
It’s what Bristol-Myers execs aren’t saying that makes one key analyst wonder about a potential buyout offer, looming Opdivo data and Plan B
Endpoints
Bristol-Myers Squibb
Celgene
M&A
Opdivo
Flag link:
Bristol-Myers urges shareholders in open letter to support $74 billion Celgene deal amid resistance
Bristol-Myers urges shareholders in open letter to support $74 billion Celgene deal amid resistance
CNBC
Bristol-Myers Squibb
M&A
Celgene
Flag link:
Bad year at Celgene? Forget about it. CEO Mark Alles nabbed a big raise as compensation gyrated to $16.2M
Bad year at Celgene? Forget about it. CEO Mark Alles nabbed a big raise as compensation gyrated to $16.2M
Endpoints
Celgene
Mark Alles
Pharma CEOs
executive pay
Flag link:
The Bristol-Myers–Squibb Deal May No Longer Be a Sure Thing, but It Will Still Likely Happen
The Bristol-Myers–Squibb Deal May No Longer Be a Sure Thing, but It Will Still Likely Happen
Barron's
M&A
Bristol-Myers Squibb
Celgene
Flag link:
Bristol-Myers’ $74B Celgene Buyout Faces Opposition from Wellington
Bristol-Myers’ $74B Celgene Buyout Faces Opposition from Wellington
Xconomy
Bristol-Myers Squibb
Celgene
M&A
Wellington
Flag link:
Celgene gets fast FDA review of Revlimid combo in lymphoma
Celgene gets fast FDA review of Revlimid combo in lymphoma
Pharmaforum
Celgene
Revlimid
FDA
Roche
Rituxan
priority review
Flag link:
Starboard plots board coup after buying into Bristol-Myers in lead-up to Celgene buyout vote
Starboard plots board coup after buying into Bristol-Myers in lead-up to Celgene buyout vote
Endpoints
Jeff Smith
Starboard
M&A
Celgene
Bristol-Myers Squibb
Flag link:
Starboard gauges Bristol-Myers shareholder support for Celgene deal
Starboard gauges Bristol-Myers shareholder support for Celgene deal
Yahoo/Reuters
Bristol-Myers Squibb
Celgene
M&A
Starboard
shareholders
Flag link:
Celgene's Revlimid defenses withstand another challenge
Celgene's Revlimid defenses withstand another challenge
Biopharma Dive
Celgene
Revlimid
Multiple Myeloma
Dr Reddy's
patents
Flag link:
Bristol-Myers' rumored activists 'haven't made a decision' on the company yet: Starboard CEO
Bristol-Myers' rumored activists 'haven't made a decision' on the company yet: Starboard CEO
Fierce Pharma
Bristol-Myers Squibb
Celgene
M&A
Starboard
Jeff Smith
Flag link:
Starboard Value Is to Take Stake in Bristol-Myers Squibb
Starboard Value Is to Take Stake in Bristol-Myers Squibb
Bloomberg
Bristol-Myers Squibb
Celgene
M&A
Starboard
Jeff Smith
Flag link:
Celgene Takes A Step Closer To Its Bristol Merger With Solid Quarter
Celgene Takes A Step Closer To Its Bristol Merger With Solid Quarter
Investors Business Daily
Celgene
earnings
Flag link:

Pages